Butterfly Medical Announces Completion of Pivotal Trial for Minimally Invasive Treatment of Benign Prostatic Hyperplasia
Results from a comprehensive study involving 244 patients will support plans for FDA Pre-Market Approval (PMA) application. Butterfly Medical, known for its innovative and non-invasive solutions for benign prostatic hyperplasia (BPH), has successfully concluded its pivotal clinical trial, which includes a final 12-month follow-up with all participants. This significant study has been designed to assess the safety and effectiveness of the Butterfly Prostatic Retraction Device, representing a cutting-edge option for men suffering from BPH.
The Significance of the Study
The double-blind, randomized controlled trial (RCT) involved 244 patients who tried the Butterfly Prostatic Retraction Device, a minimally invasive implant that mechanically retracts the lateral lobes of the prostate. This procedure seeks to restore natural urinary flow without resorting to traditional invasive methods.
Patrick MacCarthy, CEO of Butterfly Medical stated, "This trial marks a critical step in validating the Butterfly Prostatic Retraction Device as a safe and effective solution that avoids the limitations of early-generation BPH treatments. Our extensive follow-up data reinforces the device’s promise as a long-term solution for men plagued by BPH symptoms. We are eager to fulfill a pressing need within the global urology market thanks to the collaboration of 244 dedicated patients and our clinical partners."
The Prevalence of BPH and Existing Solutions
BPH affects nearly half of men aged 51 to 60 and escalates to as much as 90% in men over 80. Nonetheless, many individuals battling this condition often find themselves underserved. Traditional drug therapies commonly demand lifelong adherence and may lead to bothersome side effects such as dizziness and sexual dysfunction.
Moreover, conventional surgical interventions typically involve tissue removal, which is not only invasive but also requires longer recovery times. There exists considerable dissatisfaction among men who wish to avoid surgery but feel let down by medication. Dr. James C. Ulchaker, Chief Medical Officer at Butterfly Medical, remarked, "The Butterfly device provides a necessary alternative. It accommodates diverse prostate sizes while adhering to the natural anatomy, thus restoring urinary flow without cutting or burning tissue. Achieving completion of this pivotal trial brings us closer to introducing a safe, effective, and reversible minimally invasive therapy solution for patients."
Regulatory Status and Future Prospects
The Butterfly Prostatic Retraction Device has already received CE Mark approval for use within the European Union, affirming its safety and efficacy in patients. However, it remains an investigational device in the U.S., not yet cleared for commercial distribution.
About Butterfly Medical
Butterfly Medical strives to revolutionize the treatment landscape for benign prostatic hyperplasia. Their flagship product aims to restore natural urinary flow and deliver long-lasting alleviation from BPH symptoms, ultimately enhancing the quality of life for patients. The Butterfly Medical device is CE Mark certified, while in the United States it is utilized for investigational purposes only as per federal regulations. The company endeavors to set a new standard of care by providing alternatives to both medication and standard surgical procedures for countless men globally.
For additional insights, please visit their official site. Butterfly Medical is also on LinkedIn and welcomes connections and inquiries.
Frequently Asked Questions
What is the Butterfly Prostatic Retraction Device?
This device is a minimally invasive solution aimed at addressing the symptoms of benign prostatic hyperplasia (BPH) by mechanically retracting prostate lobes.
How many patients participated in the trial?
The trial included 244 patients who were part of a randomized controlled study to assess the device's effectiveness.
What are the common side effects of existing BPH treatments?
Current treatment options can lead to side effects such as dizziness, sexual dysfunction, and may require long-term adherence.
Is the device available in the U.S.?
No, the device is currently investigational and not approved for commercial sale in the U.S.
What certifications does the Butterfly device hold?
The device is CE Mark approved for use in the European Union, showcasing its compliance with health and safety standards.
